Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

Fudan University

Status and phase

Enrolling

Early Phase 1

Conditions

Acne Vulgaris

Treatments

Drug: dihydroartemisinin

Study type

Interventional

Funder types

Other

Identifiers

NCT07007078

B2025-113R

Details and patient eligibility

About

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is:

• Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris.

Participants will:

Take DHA every day for 3 months
Visit the clinic once every month for checkups and tests

Enrollment

60 estimated patients

Sex

All

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinically diagnosed with acne vulgaris;
For female patients, no pregnancy plans within the next 6 months.

Exclusion criteria

Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months;
Patients who have used topical medications for acne within the past 2 weeks;
Pregnant or breastfeeding women;
Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.